Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Short Interest Update

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) saw a large decline in short interest in April. As of April 15th, there was short interest totalling 1,760,000 shares, a decline of 13.7% from the March 31st total of 2,040,000 shares. Based on an average daily trading volume, of 629,900 shares, the short-interest ratio is currently 2.8 days.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Wedbush boosted their price objective on Black Diamond Therapeutics from $10.00 to $16.00 and gave the stock an “outperform” rating in a research note on Monday, April 8th. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective (up from $11.00) on shares of Black Diamond Therapeutics in a research note on Monday, March 18th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in BDTX. Jump Financial LLC acquired a new position in shares of Black Diamond Therapeutics during the 3rd quarter worth approximately $32,000. Algert Global LLC acquired a new position in Black Diamond Therapeutics in the third quarter valued at approximately $57,000. Pale Fire Capital SE acquired a new position in Black Diamond Therapeutics in the fourth quarter valued at approximately $144,000. Citigroup Inc. acquired a new position in Black Diamond Therapeutics in the third quarter valued at approximately $176,000. Finally, Cornercap Investment Counsel Inc. acquired a new position in Black Diamond Therapeutics in the fourth quarter valued at approximately $233,000. 95.47% of the stock is currently owned by institutional investors and hedge funds.

Black Diamond Therapeutics Trading Up 15.3 %

Shares of Black Diamond Therapeutics stock traded up $0.78 on Friday, hitting $5.89. 567,043 shares of the company were exchanged, compared to its average volume of 471,335. The company has a 50-day moving average price of $4.93 and a 200 day moving average price of $3.50. Black Diamond Therapeutics has a 1-year low of $1.43 and a 1-year high of $6.85.

Black Diamond Therapeutics (NASDAQ:BDTX) last issued its earnings results on Tuesday, March 12th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.13. Analysts predict that Black Diamond Therapeutics will post -1.71 EPS for the current fiscal year.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.